Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note issued to investors on Tuesday. The firm issued a sell rating on the stock.

Bio-Path Price Performance

Shares of BPTH opened at $0.87 on Tuesday. The business’s 50 day simple moving average is $0.89 and its 200-day simple moving average is $1.11. Bio-Path has a one year low of $0.59 and a one year high of $9.99.

Institutional Investors Weigh In On Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC bought a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 5.74% of the company’s stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.